PRNewsWire
12 Jun 2026, 08:05 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Volta Labs has launched an automated App for Twist Bioscience's Fast Hybridization Kit on the Callisto Sample Prep System. — Automation of complex NGS workflows reduces labor costs and errors, potentially increasing the adoption rate of Twist Bioscience's consumables.
+0.30The new automation allows labs to move from traditional overnight hybridization to a same-day, sample-to-sequencer workflow. — Faster turnaround times for cancer profiling and exome sequencing increase lab throughput and efficiency.
+0.20Testing indicates that the automated Callisto process delivers sequencing performance and QC metrics equivalent to manual preparation. — Removing the performance penalty typically associated with automation lowers the barrier for labs to switch from manual to automated systems.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company expanded its hybrid capture portfolio through a new automation partnership, increasing accessibility and efficiency for customers.
Mentioned as a supported sequencing platform for Volta Labs' system, indicating broad ecosystem compatibility.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
1h ago
